Table 2.
Baseline characteristics of patients with LTP versus non-LTP of HCC after RFA
| Variables | LTP (n=8) | Non-LTP (n=58) | p value |
|---|---|---|---|
| Age (years)* | 71.9±12.0 (53.2-82.7) | 69.8±10.8 (38.1-91.7) | 0.404 |
| Gender (male,%) | 5 (62.5) | 38 (65.5) | 0.867 |
| Virus/alcoholic/cryptogenic (%) | 8/0/0 (100/0/0) | 48/4/6 (82.8/6.9/10.3) | 0.719 |
| Cirrhosis (%) | 7 (87.5) | 46 (79.3) | 0.688 |
| Chronic hepatitis/Child A/B/C | 1/7/0/0 (12.5/87.5/0/0) | 12/34/11/1 (20.7/58.6/19.0/1.7) | 0.448 |
| Treatment naive (%) | 6 (75.0) | 48 (82.8) | 0.630 |
| PT/INR* | 1.1±0.1 (1.0-1.2) | 1.2±0.1 (0.9-1.5) | 0.054 |
| Bilirubin total (mg/dl)* | 0.75±0.41 (0.4-1.7) | 0.97±0.70 (0.2-3.5) | 0.385 |
| Albumin (g/dl)* | 3.86±0.48 (3.30-4.60) | 3.64±0.61 (2.38-4.61) | 0.556 |
| AFP (ng/ml)* | 1297±3354 (4-9587) | 345±1152 (1-5270) | 0.049 |
| Creatinine (mg/dl)* | 0.93±0.24 (0.54-1.21) | 0.97±0.90 (0.4-7.13) | 0.256 |
| ALT (U/l)* | 45±42 (14-144) | 54±45 (10-203) | 0.401 |
| Platelet count (k)* | 120±68 (52-263) | 124±60 (38-322) | 0.791 |
| Tumor size (mm)* | 28±12 (19-48) | 23±10 (8-49) | 0.143 |
| Close to vessel (%) | 4 (50.0) | 20 (34.5) | 0.448 |
| Close to subcapsular/organ (%) | 4 (50.0) | 30 (51.7) | 0.927 |
| Use of artificial ascites/effusion (%) | 5 (62.5) | 16 (27.6) | 0.047 |
| Estimated ablation volume with safety margin of 5 mm (cm3) | 37.6±38.5 (12.8-102.2) | 24.0±22.2 (3.1-107.5) | 0.140 |
| Post-RFA ablation volume (cm3) | 37.8±19.7 (16.0-68.4) | 46.2±38.9 (6.2-223.5) | 0.937 |
| Ablation volume ≥ safety margin of 5 mm (%) | 4 (50.0) | 51 (87.9) | 0.007 |
LTP = local tumor progression; PT = prothrombin time; INR = international normalized ratio; AFP = alpha-fetoprotein; ALT = alanine aminotransferase; RFA = radiofrequency ablation.
*
Given as mean ± SD (range).